Cardiac and Psycho-vegetative Abnormalities During Menopause Period and the Ways for Their Therapeutic Correction
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to study the features of cardiac and autonomic symptoms in women in climacteric period and determination of the effectiveness of Maksipim in the correction of violations.
Patients and methods. There were examined 62 patients perimenopausal and postmenopausal period of life between the ages from 48 to 67 years (average age of 51.2±7,42 years). Women in the control group (n=32) received conventional therapy according to the standards (nitrates, beta-blockers, ACE inhibitors, statins). Women of the controlled group (n=30) on the background of basic therapy were receiving additional Maksipim (STADA, Germany) (active substance 3-hydroxy-6-methyl-2-ethylpyridine succinate) for 5 ml intravenously once a day, 5 injections, then oraly 1 tablet (0.125 g) 3 times a day for 1 month.
Results. The results of these studies showed that menopause lipid disorders, clinical manifestations of angina, presence of hypertension and psycho-vegetative disorders.
Conclusion. Application in complex therapy of patients with coronary heart disease (CHD) combined with arterial hypertension in the menopausal period of the drug Maksipim, helps normalize lipid metabolism, reduce the clinical manifestations of CHD, decrease of blood pressure. Concurrent use Maksipim helps to eliminate manifestations of somatic vegetative and psycho-vegetative disorders, which favorably affects the quality of patients’ life.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Бобров В.О., Жарінов О.Й., Давидова І.В. Артеріальна гіпертензія в осіб літнього віку: особливості діагностики, диференційоване лікування: Методичні рекомендації. – К., 2000. – 20 с.
Гаспарян Н.Д., Королева A.B. Перименопауза – критический период в жизни женщины // Рос. вестник акушера-гинеколога. – 2004. – № 3. – С. 23-26.
Зуева Н.А. Основные принципы лечения артериальной гипертензии при метаболическом синдроме // Здоров’я України. – 2004. – № 6. – С. 12.
Катеренчук І.П. Артеріальна гіпертензія у жінок різного віку. – Полтава. – 2013. – 268 с.
Костенко Е.В., Петрова Л.В., Зайцев К.А и др. Опыт применения антиоксидантной терапии (мексиприм) при лечении больных в раннем восстановительном периоде ишемического инсульта полушарной локализации // РМЖ. – 2010. – № 18. – С. 1-5.
Кукес В., Шиллер Л., Хаджиева Б., Беляева С. Применение препарата Мексиприм в терапии цереброваскулярной болезни // Врач. – 2008. – № 3. – С. 55-61.
Свищенко Е.П., Коваленко В.Н. Артериальная гипертензия. Практическое руководство. – К.: Морион, 2001. – 527 с.
Cметник В.П., Шестакова И.Г. Современные представления о менопаузальном метаболическом синдроме // Consilium medicum. – 2003. – Т. 5, № 9. – С. 543-546.
Федин А.И. Оксидантный стресс и применение антиоксидантов в неврологии // Атмосфера. Нервные болезни. – 2002.– № 2. – С. 2-12.
Шальнова А.С., Оганов Р.Г., Деев А.Д. Оценка и управление суммарным риском сердечно-сосудистых заболеваний у населения России // Кардиоваск. терапия и профил. – 2004. – № 4. – С. 4-11.
Avis N.E., Brambilla D., McKinlay S.M., Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusette women’s Health Study // Ann. Epidemiol. – 1994. – Vol. 4, – N 3. – P. 214-220.
Bainton D., Miller N., Bolton C.H. et al. Plazma treglyceride and high density lipoprotein cholesterol as predictors of ischemic heart disease in British men // Br. Heart J. – 1992. – Vol. 68. – P. 60–66.
Barford A., Dorling D., Smith G.D., Shaw M. Life expectancy: women now on top everywhere // British Medical Journal. – 2006. – V. 332. – P. 1095–1096.
Cho G.J., Park H.T., Shin J.H. et al. The relationship between reproductive factors and metabolic syndrome in Korean postmenopausal women: Korea National Health and Nutrition Survey 2005 // Menopause. – 2009. – V. 16. – P. 998–1003.
Gardin J.M., Wagenknecht L.E., Anton-Culver H et al. Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study Coronary Artery Risk Development in Young Adults // Circulation. – 1995. – V. 92. – P. 380–387.
Grohé C., Kahlert S., Löbbert K., Vetter H. Expression of estrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis // J. Endocrinol. – 1998. – V. 156. – P. 1–7.
Grohé C., Kahlert S., Löbbert K. et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors // FEBS Lett. – 1997. – V. 416. – P. 107–112.
Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertens. – 2003. – V. 21. – P. 1011–1053.
Jiang C., Poole-Wilson P.A., Sarrel P.M. et al. Effect of 17 beta-estradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea pig isolated cardiac myocytes // Br. J. Pharmacol. – 1992. – V. 106. – P. 739-745.
Lobo R.A. Менопауза: сучасні терапевтичні підходи // Медицина світу. – 2011. – Т. 11. – С. 295-309.
Rosano G.M.S., Sarrel P.M., Cheirchia S.L. et al. Benefitial effect of estrogen on exercise-induced myocardial ischemia in women with coronary artery disease // Lancet. – 2000. – V. 342. – P. 133-136.
Schmidt P.J., Roca C.A., Bloch M., Rubinow D.K. The perimenopause and affective disorders // Semin Reprod Endocrinol. – 1997. – V. 15. – № 1. – P. 91-100.
Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale // Acta Psychiatr. Scand. – 1983. – V. 67. – P. 361-370.
